To model EGFR-TKI resistance in vitro, we developed an acquired osimertinib resistant subline derived from HCC827 NSCLC cells, which harbor an activating EGFR mutation (exon 19, del746–750). This evidence concerns the gene EGFR and non-small cell lung carcinoma.